Cargando…
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
BACKGROUND: Currently, booster dose is needed after 2 doses of non-live COVID-19 vaccine. With limited resources and shortage of COVID-19 vaccines, intradermal(ID) administration might be a potential dose-sparing strategy. OBJECTIVE: To determine immunologic response and reactogenicity of ID ChAdOx1...
Autores principales: | Nantanee, Rapisa, Aikphaibul, Puneyavee, Jaru-Ampornpan, Peera, Sodsai, Pimpayao, Himananto, Orawan, Theerawit, Tuangtip, Sophonphan, Jiratchaya, Tovichayathamrong, Punyot, Manothummetha, Kasama, Laohasereekul, Tysdi, Hiransuthikul, Narin, Hirankarn, Nattiya, Puthanakit, Thanyawee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058819/ https://www.ncbi.nlm.nih.gov/pubmed/35513961 http://dx.doi.org/10.1016/j.vaccine.2022.04.067 |
Ejemplares similares
-
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022) -
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
por: Nanthapisal, Sira, et al.
Publicado: (2022) -
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022) -
Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand
por: Aikphaibul, Puneyavee, et al.
Publicado: (2020) -
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
por: Nantanee, Rapisa, et al.
Publicado: (2023)